2016-11-07T11:19:40-06:00 2015-12-31 263839190 BURR PILGER MAYER INC 60 SOUTH MARKET STREET SUITE 800 SAN JOSE CA 95113 990 2015-01-01 204284925 QUANTUM LEAP HEALTHCARE COLLABORATIVE QUAN 4159140363 3450 CALIFORNIA STREET SAN FRANCISCO CA 941181837 DAVE MANDELKERN COO 4159140363 2016-11-03 1 MICHAEL STEPHEN SCHAFFER P00210063 4089616300 2016-11-03 2015 2017-02-10 21:41:12Z DAVE MANDELKERN 3450 CALIFORNIA STREET SAN FRANCISCO CA 941181837 9066877 0 X WWW.QUANTUMLEAPHEALTH.ORG X 2005 CA THE MISSION OF QUANTUM LEAP HEALTHCARE COLLABORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 8 3 9 3 0 0 266491 808721 1974867 8257957 299 199 0 0 2241657 9066877 30500 50000 0 0 737692 1069313 0 26888 152819 9533288 12552836 10301480 13699037 -8059823 -4632160 5173469 6493314 5265643 11198715 -92174 -4705401 X THE MISSION OF QUANTUM LEAP HEALTHCARE COLLABORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 0 0 12395774 8257957 I-SPY 2 (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS 2) IS A CLINICAL TRIAL FOR WOMEN WITH NEWLY DIAGNOSED LOCALLY ADVANCED BREAST CANCER. THE TRIAL TESTS WHETHER ADDING INVESTIGATIONAL DRUGS TO STANDARD CHEMOTHERAPY IS BETTER THAN STANDARD CHEMOTHERAPY ALONE BEFORE HAVING SURGERY. THE TREATMENT PHASE OF THIS TRIAL TESTS MUTIPLE INVESTIGATIONAL DRUGS THAT ARE THOUGHT TO TARGET THE BIOLOGY OF EACH PARTICIPANT'S TUMOR. QUANTUM LEAP HAS MADE SIGNIFICANT FINANCIAL INVESTMENT IN THIS IMPORTANT TRIAL AND IS THE CO-PROJECT MANAGER. 370886 ATHENA NETWORK (WWW.ATHENANETWORK.ORG) IS A VERY LARGE, MULTI-STATE PROJECT WITHIN THE UNIVERSITY OF CALIFORNIA. ATHENA'S MISSION IS TO TRACK UP TO 150,000 WOMEN WITH BREAST CANCER OVER A LONG PERIOD OF TIME TO FIND GENETIC MARKERS FOR BREAST CANCER. QUANTUM LEAP HAS BEEN PROVIDING PROJECT MANAGEMENT AND TECHNOLOGY EXPERTISE TO ATHENA SINCE ITS INCEPTION. 238570 50000 BREASTCANCERTRIALS.ORG/CTMATCH: BREASTCANCERTRIALS.ORG IS AN ONLINE SERVICE THAT HELPS PATIENTS FIND BREAST CANCER TRIALS PERSONALIZED TO THEIR SITUATION BY MATCHING THEIR HISTORIES TO TRIAL ELIGIBILITY CRITERIA. CTMATCH IS A CUSTOMIZABLE, TECHNOLOGY PLATFORM THAT SUPPORTS CLINICAL TRIAL MATCHING ACROSS ALL CANCERS. THE BOSTON VETERAN'S ADMINISTRATION MEDICAL CENTER IS USING CTMATCH TO SUPPORT ITS LUNG CANCER CLINICAL TRIAL MATCHING APPLICATION. 56027 BREAST CANCER TRIALS (BCT) (WWW.BREASTCANCERTRIALS.ORG) IS A FREE WEB SERVICE THAT ALLOWS PATIENTS WITH ADVANCED BREAST CANCER TO FIND AND SUBSCRIBE TO ELIGIBLE CLINICAL TRIALS AND ADVANCED TREATMENTS. QUANTUM LEAP HAS BEEN INVOLVED WITH BCT SINCE THE INITIAL DEVELOPMENT OF ITS WEBSITE. SINCE ITS NTAIONAL LAUNCH IN 2009, QUANTUM LEAP HAS BEEN OPERATING AND MAINTAINING THE SERVICE.I-SPY 3 IS INTENDED TO BE A PHASE 3 CLINICAL TRIAL TO CONTINUE TO TEST WHETHER ADDING INVESTIGATIONAL DRUGS TO STANDARD CHEMOTHERAPY IS BETTER THAN STANDARD CHEMOTHERAPY BEFORE HAVING SURGERY. 56027 13061257 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 0 0 0 1 24 0 9 1 0 0 0 0 0 0 0 0 0 0 X 8 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 1 1 0 CA X X THE ORGANIZATION 4159140363 3450 CALIFORNIA STREET SAN FRANCISCO CA 941181837 ANNA BARKER DIRECTOR 0.50 X 0 0 0 SUE FOLEY DIRECTOR/CEO (NOV - DEC 2015) 0.50 X 41667 0 0 JEFF PFEFFER DIRECTOR 0.50 X 0 0 0 ROBYN RUTLEDGE DIRECTOR 0.50 X 0 0 0 ALAN HU DIRECTOR, PRES & CEO (TO JUL 2015) 40.00 X X 58333 0 17588 LAURA ESSERMAN TREASURER 10.00 X X 0 0 0 BOB PATTERSON DIRECTOR & SECRETARY 5.00 X X 0 0 0 CABOT BROWN DIRECTOR/CEO (FROM DEC 2015) 40.00 X X 30000 0 0 MELISSA PAOLONI ED OF CLINICAL ACTIVITIES 40.00 X 180000 0 953 THOMAS BECHTOLD INFORMATION TECHNOLOGY ARCHITECT 30.00 X 159000 0 0 469000 0 18541 2 0 1 0 0 808721 808721 SPECIALIZED PROGRAMMIN 541511 8257957 8257957 8257957 199 199 9066877 8257957 0 199 50000 50000 328542 235801 88181 4560 620213 435949 176422 7842 57763 55769 1994 62795 44140 17755 900 119037 119037 1702 1612 90 26888 26888 741552 494567 169651 77334 5247 5187 60 3896 3308 588 16253 16253 42611 41515 1096 1224 200 1024 22889 18156 4733 RESEARCH SITES 8990345 8990345 PROGRAM MANAGEMENT 2567695 2534484 33211 RESEARCH 30800 30800 MISCELLANEOUS 9585 387 9198 13699037 13061257 484961 152819 1399758 2249237 1990703 0 1050000 18000 697260 4196222 32285 27616 4849 2610 3463 2239 5173469 6493314 4915643 3154237 350000 330000 0 7714478 5265643 11198715 X -1247827 -5284127 1155653 578726 -92174 -4705401 5173469 6493314 -4632160 18933 0 X X 0 1 X 1 0 X 1739334 1830750 6252298 266491 808721 10897594 1739334 1830750 6252298 266491 808721 10897594 8800742 2096852 50 1291 81 299 199 1920 10899514 10263424 0.19240 0.17160 X THE QUANTUM LEAP HEALTHCARE COLLABORATIVE BELIEVES THAT IT SATISFIES THE FACTS AND CIRCUMSTANCES TEST AND QUALIFIES AS A PUBLIC CHARITY. THE ORGANIZATION HAS AN ESTABLISHED RECORD OF RECEIVING PUBLIC SUPPORT AND HAS MET ITS EXEMPT PURPOSE BY PROVIDING SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS. THE ORGANIZATION HAS PLANS TO INCREASE THEIR PUBLIC SUPPORT PERCENTAGE. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 4849 2610 2239 2239 CLINICAL TRIAL ACCOUNTS 7714478 7714478 X X 1 HORNTHAL & CO 2234 BEACH STREET SAN FRANCISCO CA 94123 DONOR SOLICITATIONS 0 850733 28688 822045 850733 28688 822045 CA 1 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 4900 BROADWAY STE 1150 SACRAMENTO CA 95820 946036494 501(C)(3) 25000 BCT TECHNOLOGY (IT) SUPPORT 1 0 X 0 0 0 0 0 0 0 0 0 MELISSA PAOLONI ED OF CLINICAL ACTIVITIES 180000 0 0 0 0 0 0 0 953 0 180953 0 0 0 THOMAS BECHTOLD INFORMATION TECHNOLOGY ARCHITECT 159000 0 0 0 0 0 0 0 0 0 159000 0 0 0 ROBERT HU FAMILY OF DIRECTOR, PRESIDENT & CEO 12240 A BROTHER OF THE DIRECTOR, PRESIDENT & CEO PERFORMED IT CONSULTING SERVICES. 0 FORM 990, PART VI, SECTION B, LINE 11 FORM 990 IS PREPARED BY AN INDEPENDENT CPA FIRM IN CONJUNCTION WITH THE ORGANIZATION'S ACCOUNTANT. A DRAFT OF FORM 990 IS REVIEWED BY THE ACCOUNTANT, AND CORRECTIONS/MODIFICATIONS ARE MADE BY THE OUTSIDE CPA. THE REVISED DRAFT IS THEN REVIEWED BY THE ACCOUNTANT. ANY CONCERNS ARE RAISED WITH THE CPA FIRM AND A CONSENSUS IS ACHIEVED. BOARD MEMBERS ARE SENT A COPY OF THE TAX RETURN PRIOR TO FILING FOR THEIR REVIEW. THE RETURN IS THEN FINALIZED AND ELECTRONICALLY FILED WITH THE TAXING AUTHORITIES. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS PRESENTED AND REVIEWED AT THE ANNUAL BOARD MEETING. EACH BOARD MEMBER IS REQUIRED TO ACKNOWLEDGE IN WRITING THAT NO CONFLICT EXISTS. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF THE PRESIDENT OF THE BOARD OF THE ORGANIZATION WAS DETERMINED AND APPROVED BY VOTE OF THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. PERSONNEL OF UCSF REVIEWED JOB REQUIREMENTS AGAINST TECHICAL ABILITIES OF SUBCONTRACTORS AND DETERMINED WHETHER OR NOT THEY MATCHED. ALL SUBCONTRACTORS WERE ENGAGED BELOW-MARKET RATES. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS, AUDITED FINANCIAL STATEMENTS AND FORM 990, RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, ARE PROVIDED UPON WRITTEN REQUEST THROUGH THE QUANTUM LEAP HEALTHCARE WEBSITE. FORM 990 & PENDING AUDITED FINANCIAL STATEMENTS: QUANTUM LEAP HEALTHCARE COLLABORATIVE IS UNDERGOING AN AUDIT FOR THE PERIOD ENDING DECEMBER 31, 2015. AS OF THE FILING DATE, THE AUDIT IS NOT COMPLETE. THE ORGANIZATION PLANS TO FILE A TIMELY AMENDED FORM 990 TO REFLECT ANY MODIFICATIONS MADE AS A RESULT OF THE FINALIZED AUDIT. FORM 990, PART XII, LINE 2C: THE ROLE OF THE AUDIT COMMITTEE HAS NOT CHANGED FROM THE PRIOR YEAR. CENTER FOR CLINICAL INNOVATION DBA ENCOMPASS HEALTH FOUNDATION 320 FAIRWAY DRIVE HALF MOON BAY CA 94019 461637647 FUNDING CLINICAL RESEARCH AND INITIATIVES CA 501(C)(3) LINE 7 QUANTUMLEAP HEALTHCARE COLLABORATIVE 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0